No Data
No Data
Atossa Therapeutics Gives Final Dose in Breast Cancer Prevention Study | NASDAQ:ATOS
Atossa Therapeutics Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced that the last patient in the Company's Karisma-Endoxifen clinical trial
Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating
Express News | Cantor Fitzgerald Reiterates Overweight on Atossa Therapeutics
Express News | Atossa Therapeutics Files for Mixed Shelf of up to $100 Mln - SEC Filing
Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Nouss : What are you in about dude ?